Oramed Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Oramed Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	21.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	24 Jan 2024

Recent future growth updates

Recent updates

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23

Oramed And The Hurdles Of Developing Oral Insulin

Dec 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Oct 04

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21

Oramed reaches 50% enrollment in late-stage oral insulin study

Jun 08

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06

The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It

Feb 12

Oramed Pharmaceuticals EPS beats by $0.42, revenue in-line

Jan 14

Why Oramed Pharmaceuticals' (NASDAQ:ORMP) CEO Pay Matters

Jan 08

Oramed's obesity drug candidate shows decrease in glucose levels

Dec 23

We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth

Dec 04

Earnings and Revenue Growth Forecasts

NasdaqCM:ORMP - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	1	-11	N/A	N/A	2
12/31/2023	1	6	-11	-10	N/A
9/30/2023	2	-16	-17	-17	N/A
6/30/2023	3	-20	-19	-18	N/A
3/31/2023	3	-30	-25	-24	N/A
12/31/2022	3	-37	-28	-28	N/A
9/30/2022	3	-46	-39	-39	N/A
6/30/2022	3	-46	-43	-43	N/A
3/31/2022	3	-40	-39	-39	N/A
12/31/2021	3	-35	-33	-33	N/A
11/30/2021	3	-25	-22	-22	N/A
8/31/2021	3	-22	-22	-21	N/A
5/31/2021	3	-18	-18	-17	N/A
2/28/2021	3	-15	-16	-15	N/A
12/31/2020	3	-22	-26	-25	N/A
11/30/2020	3	-15	-16	-16	N/A
8/31/2020	3	-12	-13	-12	N/A
5/31/2020	3	-11	-13	-13	N/A
2/29/2020	3	-13	-14	-14	N/A
11/30/2019	3	-13	-12	-12	N/A
8/31/2019	3	-14	-13	-13	N/A
5/31/2019	3	-15	-14	-14	N/A
2/28/2019	3	-15	-14	-14	N/A
11/30/2018	3	-14	-16	-16	N/A
8/31/2018	2	-13	-15	-15	N/A
5/31/2018	2	-12	-12	-12	N/A
2/28/2018	2	-10	-11	-11	N/A
11/30/2017	2	-10	N/A	-10	N/A
8/31/2017	2	-10	N/A	-6	N/A
5/31/2017	2	-13	N/A	3	N/A
2/28/2017	2	-13	N/A	3	N/A
11/30/2016	1	-11	N/A	8	N/A
8/31/2016	1	-11	N/A	5	N/A
5/31/2016	0	-8	N/A	-3	N/A
2/29/2016	0	-8	N/A	-2	N/A
11/30/2015	N/A	-8	N/A	-6	N/A
8/31/2015	N/A	-7	N/A	-5	N/A
5/31/2015	N/A	-7	N/A	-5	N/A
2/28/2015	N/A	-7	N/A	-5	N/A
11/30/2014	N/A	-6	N/A	-5	N/A
8/31/2014	N/A	-6	N/A	-4	N/A
5/31/2014	N/A	-5	N/A	-4	N/A
2/28/2014	N/A	-4	N/A	-4	N/A
11/30/2013	N/A	-4	N/A	-3	N/A
8/31/2013	N/A	-4	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ORMP's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if ORMP's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ORMP's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ORMP's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ORMP's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ORMP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Oramed Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 50%

Consensus EPS estimates upgraded to US$0.34 loss

Consensus EPS estimates fall by 13%

Consensus EPS estimates upgraded to US$0.35 loss

Price target decreased by 82% to US$2.40

Consensus EPS estimates upgraded to US$0.59 loss

Recent updates

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 50%

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New minor risk - Market cap size

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Consensus EPS estimates upgraded to US$0.34 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates fall by 13%

Consensus EPS estimates upgraded to US$0.35 loss

Price target decreased by 82% to US$2.40

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

President recently bought US$201k worth of stock

Independent Director recently bought US$142k worth of stock

Consensus EPS estimates upgraded to US$0.59 loss

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 23% to US$15.16

Price target decreased to US$21.67

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Price target decreased to US$28.67

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate

Oramed to hand Korean rights for insulin capsule

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Reaches 50% Enrollment in Its Second Phase 3 Oral Insulin Trial

High number of new and inexperienced directors

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Oramed Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2022

Oramed Pharmaceuticals Inc. Appoints Anne Peters to Its Scientific Advisory Board

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study Ora-D-013-1

Price target increased to US$32.50

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed Pharmaceuticals Inc. Grants NASH Patent in Europe

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Independent Chairman of the Board recently sold US$94k worth of stock

Consensus forecasts updated

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Oramed And The Hurdles Of Developing Oral Insulin

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral Covid-19 Vaccine Trial in South Africa

Full year 2021 earnings: EPS and revenues miss analyst expectations

Oramed Pharmaceuticals Inc. Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Independent Chairman of the Board recently sold US$443k worth of stock

Independent Director Xiaoming Gao has left the company

Oramed Pharmaceuticals Inc. Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Independent Chairman of the Board exercised options to buy US$1.1m worth of stock.

Price target increased to US$24.20

Consensus forecasts updated